Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bowman Cox

Executive Editor

Washington, DC
Bowman Cox leads the Pink Sheet's coverage of pharmaceutical manufacturing quality issues. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to drug manufacturers and their quality organizations.
Set Alert for Articles By Bowman Cox

Latest From Bowman Cox

COVID-19 Vaccines, Therapies Would Get Billion-Dollar Manufacturing Platform Under House Bill

House coronavirus legislation would boost domestic manufacturing capacity while further scrutinizing global supply chain.

Coronavirus COVID-19 Legislation

Supply Chain Resilience Measures Included In Senate Coronavirus Bill

Whether major drug shortages result from the COVID-19 pandemic or not, manufacturers would face greater reporting requirements, especially for APIs.

Coronavirus COVID-19 Legislation

Cipla Plant Gets FDA Warning Letter

Despite the stain on Cipla’s compliance record, the company leads on drug quality in India, with major concerns raised in only 3% of FDA inspections, compared to 11% generally.

Manufacturing India

API In Ducts And Filters Led To Cipla’s First Drug GMP Warning Letter

Despite the stain on Cipla’s compliance record, the company leads on drug quality in India, with major concerns raised in only 3% of FDA inspections, compared to 11% generally.

Manufacturing Quality

Trump Counts On China To Deliver In The Day Of The Coronavirus

President dismisses fears of drug shortages as White House prepares to deliver US from dependence on China’s pharmaceutical manufacturing complex.

Coronavirus COVID-19 Manufacturing

China’s Global Pharma Supply Chain Operations Resuming In Wake Of Outbreak, USP Says

USP reference standard sales showed slow resumption of API manufacturing in China and less-than-expected API use in India.

Generic Drugs Ingredients
See All
UsernamePublicRestriction

Register